Focused protein degradation is staying explored as a substitute technique in cancer, whereby the normal protein degradation system is co-opted for therapeutic applications. Not long ago produced novel molecules called proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One particular ligand binds to your ‘protein https://www.directivepublications.org/journal-of-clinical-breast-cancer/